Severe hypocalcemia after denosumab in a patient with acquired Fanconi syndrome.
Osteoporos Int
; 25(3): 1187-90, 2014 Mar.
Article
en En
| MEDLINE
| ID: mdl-24158473
ABSTRACT
We report the case of a 48-year-old man with acquired Fanconi syndrome due to IgG-kappa monoclonal gammopathy, who received a single dose of denosumab 60 mg for secondary prevention of skeletal fractures, in conjunction with oral calcium and vitamin D supplementation. The treatment was complicated with a severe, symptomatic hypocalcemia occurring 1 month after the injection and necessitating 4 weeks of intravenous calcium gluconate therapy. Similarly to bisphosphonates, inhibitors of the receptor activator of nuclear factor kappa-B ligand may not be appropriate for the treatment of acquired Fanconi syndrome and other forms of osteomalacia regardless of the degree of renal insufficiency and vitamin D levels. Clinicians should carefully interpret the radiographic and bone densitometry results in light of diverse mechanisms of bone demineralization and potential dependence of calcium homeostasis on high bone turnover.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Conservadores de la Densidad Ósea
/
Síndrome de Fanconi
/
Anticuerpos Monoclonales Humanizados
/
Hipocalcemia
Tipo de estudio:
Etiology_studies
Límite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Osteoporos Int
Asunto de la revista:
METABOLISMO
/
ORTOPEDIA
Año:
2014
Tipo del documento:
Article
País de afiliación:
Estados Unidos